ArticleDiscover oncology2026
Development and validation of a robust cuproptosis related signature for primary glioma via machine learning aided by loop training and validation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioma is the most common malignant tumors in central nervous system with high mortality. Accurately predicting prognosis for patients with glioma still remains a challenge. Accumulated studies have found that cuproptosis-related genes emerged as potential biomarkers for cancer prognosis. However, their prognostic roles in primary glioma are unclear. This study aimed to develop a promising prognostic signature for primary glioma using cuproptosis-related genes.
methodsA total of 1248 patients with primary glioma were obtained from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. 101 machine learning algorithm combinations together with a loop training and validation procedure were performed to identify the optimal model termed cuproptosis-related prognostic signature (CRPS). The predictive accuracy of CRPS was evaluated through Kaplan-Meier survival curves and receiver-operator characteristic (ROC) analyses. Furthermore, we compared the performance of CRPS with common clinical features and 72 published prognostic signatures.
resultsCRPS exhibited robust predictive capability in overall survival (OS) and could serve as an independent prognostic biomarker in different cohorts including TCGA-GBMLGG (HR: 1.987, 95%CI: 1.239–3.189, p < 0.001), CGGA693 (HR: 2.374, 95%CI: 1.505–3.745, p < 0.001) and CGGA325 (HR: 2.248, 95%CI: 1.334–3.787, p = 0.002). Simultaneously, CRPS outperformed 72 published signatures and traditional clinical features. Additionally, a nomogram by the combination of CRPS and tumor grade contributes to more precise prognosis prediction.
conclusionsOur study highlights CRPS as a promising tool in prognosis evaluation, survival risk stratification and personalized clinical management for primary glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.